| scholarly article | Q13442814 |
| P50 | author | Thomas Klingebiel | Q23015767 |
| P2093 | author name string | Johann Greil | |
| Richard Schäfer | |||
| Ansgar Schulz | |||
| Erhard Seifried | |||
| Peter Bader | |||
| Karl-Walter Sykora | |||
| Peter Lang | |||
| Irene von Luettichau | |||
| Giovanna Lucchini | |||
| Selim Kuçi | |||
| Zyrafete Kuçi | |||
| Andrea Jarisch | |||
| Emilia Salzmann-Manrique | |||
| Jan Soerensen | |||
| Shahrzad Bakhtiar | |||
| Abdulrahman Alsultan | |||
| Michael Dennis | |||
| Jerry Stein | |||
| Gesine Bug | |||
| Jochen Buechner | |||
| Halvard Bonig | |||
| Oliver Basu | |||
| Agnes Kelemen | |||
| Grit Herter-Sprie | |||
| Aniko Barta | |||
| Martin Hutter | |||
| Krisztián M Kállay | |||
| Mohammad Ashab Uddin | |||
| Phil Jenkin | |||
| Raj Pol | |||
| P2860 | cites work | Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. | Q50847625 |
| Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population | Q59713756 | ||
| Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease | Q63197317 | ||
| Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors | Q70051817 | ||
| Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation | Q81298136 | ||
| Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study | Q84197372 | ||
| Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy | Q84703973 | ||
| Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease | Q87336201 | ||
| Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study | Q29617267 | ||
| Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells | Q29618766 | ||
| Prognostic value of response after upfront therapy for acute GVHD | Q33964701 | ||
| Graft-versus-host disease treatment: predictors of survival | Q34205096 | ||
| Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis | Q35760517 | ||
| How I treat refractory acute GVHD. | Q35828633 | ||
| First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation | Q36113205 | ||
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
| Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). | Q37127527 | ||
| Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease | Q37552088 | ||
| Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis | Q38696262 | ||
| 1994 Consensus Conference on Acute GVHD Grading | Q39513397 | ||
| Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey | Q40756307 | ||
| The Analysis of Failure Times in the Presence of Competing Risks | Q41031423 | ||
| Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome | Q41290373 | ||
| Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients | Q42237533 | ||
| Donor selection and release criteria of cellular therapy products. | Q44370728 | ||
| Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients | Q45308238 | ||
| Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres | Q46619100 | ||
| Good responses but high TRM in adult patients after MSC therapy for GvHD. | Q50221557 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 852-862 | |
| P577 | publication date | 2018-01-29 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). | |
| P478 | volume | 53 |
| Q64061040 | Advanced cell therapeutics are changing the clinical landscape: will mesenchymal stromal cells be a part of it? |
| Q64968972 | Cellular Therapeutics - Living Drugs: A Rising Star at the Horizon of Immunotherapy in Hematology and Oncology. |
| Q91812495 | Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients |
| Q91872118 | Clinical Translation of Mesenchymal Stromal Cell Therapy for Graft Versus Host Disease |
| Q64900793 | Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease. |
| Q56395022 | Continuing Challenges in Advancing Preclinical Science in Skeletal Cell-Based Therapies and Tissue Regeneration |
| Q58702140 | Current Strategies to Generate Human Mesenchymal Stem Cells In Vitro |
| Q64965607 | Dissecting the Pharmacodynamics and Pharmacokinetics of MSCs to Overcome Limitations in Their Clinical Translation. |
| Q91995043 | GVHD-derived plasma as a priming strategy of mesenchymal stem cells |
| Q90056972 | Mesenchymal Stem Cells Beyond Regenerative Medicine |
| Q93063192 | Mesenchymal Stem Cells as a Salvage Treatment for Severe Refractory Graft-vs-Host Disease in Children After Bone Marrow Transplantation |
| Q97519174 | Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers |
| Q90683248 | Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression |
| Q96303603 | Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation |
| Q99418862 | Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study |
| Q55410263 | Restoring T Cell Homeostasis After Allogeneic Stem Cell Transplantation; Principal Limitations and Future Challenges. |
| Q90093583 | Stem cells out of the bag: characterization of ex vivo expanded mesenchymal stromal cells for possible clinical use |
| Q55401793 | Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models. |
| Q92987959 | Targeting of CD133+ Cancer Stem Cells by Mesenchymal Stem Cell Expressing TRAIL Reveals a Prospective Role of Apoptotic Gene Regulation in Non-Small Cell Lung Cancer |
| Q92404888 | The Utilization of Freezing Steps in Mesenchymal Stromal Cell (MSC) Manufacturing: Potential Impact on Quality and Cell Functionality Attributes |
| Q91522442 | Treatment and unmet needs in steroid-refractory acute graft-versus-host disease |
| Q57174876 | Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells-Single Center Experience |
| Q90590306 | Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab |
Search more.